What's Happening?
Representative Kim Schrier (D-WA) has been named the new Co-chair of the Congressional Diabetes Caucus, taking over from Congresswoman Diana DeGette (D-CO), who held the position since 1999. This announcement was made on September 21, 2026. Breakthrough
T1D Chief Global Advocacy Officer Lynn Starr expressed gratitude for Congresswoman DeGette's extensive contributions, which included securing over $2.5 billion for T1D research through the Special Diabetes Program, advancing stem cell research, and accelerating innovative T1D therapies via the 21st Century Cures Act. Representative Schrier, a pediatrician and the only current member of Congress living with Type 1 diabetes, is seen as a highly suitable successor. Her personal and professional background is expected to provide valuable insight and leadership to the caucus, ensuring continued advocacy for the diabetes community.
Why It's Important?
The appointment of Representative Kim Schrier as Co-chair of the Congressional Diabetes Caucus is significant for the diabetes community in the U.S. Her unique perspective as both a pediatrician and an individual living with Type 1 diabetes means she possesses a deep understanding of the challenges faced by patients and their families. This lived experience is crucial for shaping effective legislation and advocating for policies that improve access to care, reduce medication costs, and accelerate research for cures. The caucus, which has grown to 246 members under previous leadership, plays a vital role in securing federal funding and legislative support for diabetes initiatives. Representative Schrier's leadership is expected to maintain and potentially enhance the caucus's effectiveness in addressing critical issues, impacting millions of Americans affected by diabetes.
What's Next?
With Representative Kim Schrier at the helm, the Congressional Diabetes Caucus is expected to continue its focus on key issues such as accelerating cures, improving access to quality care, and making diabetes management more affordable. Her leadership will likely involve bipartisan efforts to advance legislation and secure funding for diabetes research and treatment. Stakeholders, including advocacy groups like Breakthrough T1D, anticipate working closely with Representative Schrier and other caucus members to build upon past successes. The caucus will likely prioritize initiatives that reflect Representative Schrier's personal and professional insights, potentially leading to new legislative proposals aimed at addressing the day-to-day realities of managing diabetes and fostering breakthroughs in treatment and prevention.
Beyond the Headlines
Representative Schrier's appointment goes beyond a mere change in leadership; it signifies a deeper integration of personal experience into policy-making within Congress. Her role as the only pediatrician and the only member of Congress with Type 1 diabetes brings an authentic voice to the legislative process, potentially humanizing the complex medical and economic issues surrounding diabetes. This could lead to more empathetic and practical policy solutions, moving beyond theoretical discussions to address the tangible needs of patients. Her leadership may also inspire greater public awareness and reduce the stigma associated with chronic diseases, fostering a more inclusive dialogue around healthcare challenges in the U.S. The long-term impact could be a more patient-centered approach to healthcare legislation, setting a precedent for other health-related caucuses.
